MedPath

Daypro

These highlights do not include all the information needed to use DAYPRO safely and effectively. See full prescribing information for DAYPRO. DAYPRO (oxaprozin) caplets, for oral useInitial U.S. Approval: 1992

Approved
Approval ID

ea1de47e-3101-4414-817c-0a098af8988c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 17, 2022

Manufacturers
FDA

Pfizer Laboratories Div Pfizer Inc

DUNS: 134489525

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

oxaprozin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0025-1381
Application NumberNDA018841
Product Classification
M
Marketing Category
C73594
G
Generic Name
oxaprozin
Product Specifications
Route of AdministrationORAL
Effective DateNovember 17, 2022
FDA Product Classification

INGREDIENTS (8)

MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
OXAPROZINActive
Quantity: 600 mg in 1 1
Code: MHJ80W9LRB
Classification: ACTIB
METHYLCELLULOSE (100 MPA.S)Inactive
Code: 4GFU244C4J
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
POLACRILIN POTASSIUMInactive
Code: 0BZ5A00FQU
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Daypro - FDA Drug Approval Details